Related Experiment Video
Updated: Apr 4, 2026

COVID-19 Seroprevalence Test for IgG Antibody Levels Among Healthy Donors Across Different Pandemic Phases in Jeddah
Published on: June 24, 2025
Anti-JC virus seroprevalence in a Finnish MS cohort
M Kolasa1, S Hagman1, A Verkkoniemi-Ahola2
1Neuroimmunology Unit, Medical School, University of Tampere, Tampere, Finland.
Background:
The risk of progressive multifocal leukoencephalopathy (PML) caused by the JC virus (JCV) is increased in patients with multiple sclerosis receiving biological therapies.
Objectives:
To determine the seroprevalence of anti-JCV antibodies in Finnish patients with multiple sclerosis (MS) and clinically isolated syndrome and to assess the clinical risk factors for JCV seropositivity.
Methods:
The JCV seroprevalence was analyzed in 503 patients using a second-generation two-step ELISA. Sixty-seven patients underwent longitudinal serological evaluation over 4.5 years.
Results:
The overall seroprevalence of JCV was 57.4%. The seropositivity was higher in men than in women, tended to increase with age, and was not affected by different immunomodulatory therapies. However, in patients with ongoing natalizumab treatment (n = 72), the anti-JCV antibody screening index was lower than in patients without such therapy [median 0.3 (range 0.1-3.1) vs 0.6 (0.1-3.1), respectively, P = 0.01]. Over 4.5 years, 4/19 (21%) initially seronegative patients converted to seropositivity, whereas 4/48 (8.3%) initially seropositive patients reverted to seronegativity. Fluctuations in serostatus were observed in 3/67 patients.
Conclusion:
The study confirmed a high anti-JCV antibody prevalence in patients with MS and its association with age and male gender but not with disease-modifying therapies. Our data suggest that therapy with natalizumab may cause a decrease in anti-JCV antibody levels, suggesting an immunosuppressive effect of natalizumab without an impact on JCV seroprevalence. The results of studies performed until now confirm the predictive value of anti-JCV antibody measurement in the assessment of PML risk; however, changes in serostatus need to be considered.
Insights
The JC virus (JCV) antibody prevalence is high in Finnish multiple sclerosis (MS) patients, particularly men and older individuals. Natalizumab therapy may lower JCV antibody levels, indicating an immunosuppressive effect.
Area of Science:
- Neuroimmunology
- Virology
- Epidemiology
Background:
- The JC virus (JCV) poses a risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients on biological therapies.
- Understanding JCV seroprevalence is crucial for managing PML risk in MS patients.
Purpose of the Study:
- To determine anti-JCV antibody seroprevalence in Finnish patients with MS and clinically isolated syndrome.
- To identify clinical risk factors associated with JCV seropositivity.
Main Methods:
- Analyzed JCV seroprevalence in 503 patients using a second-generation two-step ELISA.
- Conducted longitudinal serological evaluation in 67 patients over 4.5 years.
Main Results:
- Overall JCV seroprevalence was 57.4%, higher in men and increasing with age.
- Natalizumab treatment was associated with lower anti-JCV antibody levels (P=0.01).
- Serostatus fluctuated over time, with conversions and reversions observed.
Conclusions:
- High anti-JCV antibody prevalence in MS patients is linked to age and male gender, not disease-modifying therapies.
- Natalizumab may decrease anti-JCV antibody levels, suggesting immunosuppression.
- Anti-JCV antibody testing is valuable for PML risk assessment, but serostatus changes require consideration.
Related Concept Videos
Cytomegalovirus Disease
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Arboviral Encephalitis
Retroviruses
Infectious Diseases and Their Occurrence
Bias in Epidemiological Studies

